Literature DB >> 16157822

Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: four-year results of an open-label extension of 2 randomized clinical trials: TAP Report No. 7.

Neil M Bressler, Susan B Bressler, Laurie A Haynes, Yong Hao, Peter K Kaiser, Joan W Miller, Joel Naor, Michael J Potter, Constantin J Pournaras, Al Reaves, Philip J Rosenfeld, Ursula Schmidt-Erfurth, Jason S Slakter, Andrew Strong, Stéphane Vannier.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16157822     DOI： 10.1001/archopht.123.9.1283

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN： 0003-9950


× No keyword cloud information.
  10 in total

Review 1.  Verteporfin: a review of its use in the management of subfoveal choroidal neovascularisation.

Authors:  Caroline Fenton; Caroline M Perry
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

2.  Decreased Visual Function Scores on a Low Luminance Questionnaire Is Associated with Impaired Dark Adaptation.

Authors:  Mohammad Yazdanie; Jason Alvarez; Elvira Agrón; Wai T Wong; Henry E Wiley; Frederick L Ferris; Emily Y Chew; Catherine Cukras
Journal:  Ophthalmology       Date:  2017-06-08       Impact factor: 12.079

Review 3.  Fibrosis and diseases of the eye.

Authors:  Martin Friedlander
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

4.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8.

Authors:  Peter K Kaiser
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-15       Impact factor: 3.117

5.  Photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD): results of the Japanese AMD Trial (JAT) extension.

Authors:  Masahito Ohji
Journal:  Jpn J Ophthalmol       Date:  2008-04-30       Impact factor: 2.447

6.  The role of the ERG in the diagnosis and treatment of Age-Related Macular Degeneration.

Authors:  Christina Gerth
Journal:  Doc Ophthalmol       Date:  2008-06-07       Impact factor: 2.379

7.  Topographical Choroidal Thickness Change Following PDT for CSC: An OCT Case Report.

Authors:  William J Wirostko; Rick N Nordgren; Adam M Dubis
Journal:  J Ophthalmol       Date:  2012-01-12       Impact factor: 1.909

8.  Treatment of age-related macular degeneration: focus on ranibizumab.

Authors:  Martin S Spitzer; Focke Ziemssen; Karl U Bartz-Schmidt; Faik Gelisken; Peter Szurman
Journal:  Clin Ophthalmol       Date:  2008-03

9.  Intravitreal Bevacizumab versus Combined Bevacizumab and Triamcinolone Acetonide for Neovascular Age-Related Macular Degeneration.

Authors:  Mohammad Riazi-Esfahani; Hamid Ahmadieh; Hooshang Faghihi; Niloofar Piri; Ramin Taei; Reza Karkhaneh; Zahra Alami-Harandi; Alireza Lashay; Ahmad Mirshahi; Mehdi Nili-Ahmadabadi; Masoud Soheilian; Masoumeh Sanagou
Journal:  J Ophthalmic Vis Res       Date:  2008-04

10.  Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization.

Authors:  Frank S Ong; Jane Z Kuo; Wei-Chi Wu; Ching-Yu Cheng; Wendell-Lamar B Blackwell; Brian L Taylor; Wayne W Grody; Jerome I Rotter; Chi-Chun Lai; Tien Y Wong
Journal:  J Pers Med       Date:  2013
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.